These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7870240)

  • 1. Immunological effects of recombinant human erythropoietin on end-stage renal disease pediatric and adult patients.
    Salvati F; Liani M; La Torre M; Golato M; Di Sciascio N; Pietrzyk J; Dyras P
    Nephron; 1994; 68(4):510-1. PubMed ID: 7870240
    [No Abstract]   [Full Text] [Related]  

  • 2. Recombinant human erythropoietin therapy in end stage renal failure.
    Watson AJ; Spivak JL
    J Clin Pharmacol; 1988 Dec; 28(12):1086-8. PubMed ID: 3072351
    [No Abstract]   [Full Text] [Related]  

  • 3. Induction of fetal hemoglobin by recombinant human erythropoietin in patients with end-stage renal disease.
    Salvati F
    Nephron; 1993; 65(2):313. PubMed ID: 7504213
    [No Abstract]   [Full Text] [Related]  

  • 4. Quality of life in end-stage renal disease patients during recombinant human erythropoietin therapy. The Canadian Erythropoietin Study Group.
    Keown PA
    Contrib Nephrol; 1991; 88():81-6; discussion 87-9. PubMed ID: 2040199
    [No Abstract]   [Full Text] [Related]  

  • 5. Resistance to recombinant human erythropoietin in a child with renal failure, cystinosis and beta-thalassaemia minor.
    Milford DV; Winterborn MH
    Nephron; 1993; 64(4):645-6. PubMed ID: 8366996
    [No Abstract]   [Full Text] [Related]  

  • 6. Resistance to recombinant human erythropoietin therapy in a child with renal failure due to primary hyperoxaluria type 1.
    Lavoratti GC; Seracini D; Pela I; Materassi M; Vichi GF; Di Lollo S; Bartolozzi G
    Nephrol Dial Transplant; 1994; 9(11):1645-8. PubMed ID: 7870357
    [No Abstract]   [Full Text] [Related]  

  • 7. Recombinant human erythropoietin in end-stage renal disease.
    Bihl G
    S Afr Med J; 2002 Aug; 92(8):565. PubMed ID: 12244602
    [No Abstract]   [Full Text] [Related]  

  • 8. Recombinant erythropoietin: does it really effect sensitization?
    Phelan DL; Hibbett S; Wetter L; Hanto DW; Mohanakumar T
    Transplant Proc; 1991 Feb; 23(1 Pt 1):409-10. PubMed ID: 1990569
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of recombinant human erythropoietin on the anemia of chronic renal failure.
    Urabe A; Takaku F; Mizoguchi H; Kubo K; Ota K; Shimizu N; Tanaka K; Mimura N; Nihei H; Koshikawa S
    Int J Cell Cloning; 1988 May; 6(3):179-91. PubMed ID: 3397592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of the anaemia of end-stage renal disease with recombinant human erythropoietin.
    Verbeelen D; Hauglustaine D; Sennesael J
    Neth J Med; 1988 Aug; 33(1-2):60-7. PubMed ID: 3247012
    [No Abstract]   [Full Text] [Related]  

  • 11. [Use of recombinant erythropoietin in the treatment of anemia of chronic renal insufficiency].
    Drüeke T; Zins B; Bererhi L; Casadevall N; Varet B
    Presse Med; 1989 Jun; 18(25):1235-7. PubMed ID: 2525772
    [No Abstract]   [Full Text] [Related]  

  • 12. Recombinant human erythropoietin in the diabetic patient.
    Friedman EA; Delano BG
    Semin Nephrol; 1990 Mar; 10(2 Suppl 1):35-9. PubMed ID: 2192415
    [No Abstract]   [Full Text] [Related]  

  • 13. [Erythropoietin, blood viscosity and hypertension in chronic kidney failure].
    Schaefer RM; Heidland A
    Dtsch Med Wochenschr; 1989 Jun; 114(26):1046-9. PubMed ID: 2661190
    [No Abstract]   [Full Text] [Related]  

  • 14. Recombinant erythropoietin: 10 years of clinical experience.
    Valderrábano F
    Nephrol Dial Transplant; 1997; 12 Suppl 1():2-9. PubMed ID: 9075222
    [No Abstract]   [Full Text] [Related]  

  • 15. Rate of progression of chronic renal failure in predialysis patients treated with erythropoietin.
    Abels R
    Semin Nephrol; 1990 Mar; 10(2 Suppl 1):20-5. PubMed ID: 2192413
    [No Abstract]   [Full Text] [Related]  

  • 16. Dose-related effects of recombinant human erythropoietin on erythropoiesis. Results of a multicenter trial in patients with end-stage renal disease.
    Bommer J; Kugel M; Schoeppe W; Brunkhorst R; Samtleben W; Bramsiepe P; Scigalla P
    Contrib Nephrol; 1988; 66():85-93. PubMed ID: 3292151
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of oral levamisole on immunological response to hepatitis B vaccine in haemodialysis patients.
    Alavian SM; Tabatabaei SV
    Aliment Pharmacol Ther; 2011 Jan; 33(1):160; author reply 161. PubMed ID: 21128985
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of renal anemia, 1960-1990.
    Koch KM; Frei U
    Adv Nephrol Necker Hosp; 1991; 20():19-30. PubMed ID: 2063711
    [No Abstract]   [Full Text] [Related]  

  • 19. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin.
    N Engl J Med; 1987 Jul; 317(4):249-51. PubMed ID: 3600716
    [No Abstract]   [Full Text] [Related]  

  • 20. Analysis of initial resistance of erythropoiesis to treatment with recombinant human erythropoietin. Results of a multicenter trial in patients with end-stage renal disease.
    Kühn K; Nonnast-Daniel B; Grützmacher P; Grüner J; Pfåffl W; Baldamus CA; Scigalla P
    Contrib Nephrol; 1988; 66():94-103. PubMed ID: 3292152
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.